immune reconstitution. 
5.0 Experimental Design 
5.1 Inclusion Criteria 
5.1.1 An identical twin pair, one of whom is seropositive for HIV, the 
other twin seronegative, by standard ELISA and Western blot 
testing. 
5.1.2 Patients with Kaposi’s sarcoma are eligible for this study, but 
must not have received any systemic therapy for KS within 4 
weeks prior to entry. The diagnosis of KS must have been 
confirmed by biopsy. 
5.1.3 Free from serious psychological or emotional illness and able 
to provide written informed consent. 
5.1.4 Anticipated survival > 3 months. 
5.1.5 18 years of age or older. 
5.2 Exclusion criteria 
5.2.1 Lymphoma 
5.2.2 Unwillingness to comply with current NIH Clinical Center 
guidelines concerning appropriate notification of all current 
sexual partners of an individual regarding his or her HIV 
positive sero-status and the risk of transmission of HIV, 
infection. 
5.2.3 Recent history of substance abuse unless evidence is provided 
of an ongoing therapeutic intervention (i.e. medical therapy or 
counseling) to control such abuse. 
5.3 Duration of Study: Three years 
[298] 
Recombinant DNA Research, Volume 16 
